

11,300 Results Any time

[PDF] [Presenter Institution Country Subject YIA-01 YIA-02 YIA ...](#)

<https://www.helicobacterkorea.org/res/files/list.pdf>

Title: Tailored eradication strategy versus concomitant therapy as the first-line for *Helicobacter pylori* eradication treatment in Korean patients: A comparative study PO-03 Soo-young Na Incheon St. Mary's Hospital, The Catholic University of Korea Korea Effective eradication regimen and duration according to the results of clarithromycin susceptibility of *Helicobacter pylori* PO-06 Yonghwan Kwon Kyungpook ...

Tailored eradication vs empirical bismuth-containing ...

<https://pubmed.ncbi.nlm.nih.gov/31857776>

Abstract. Background: Few studies have compared the efficacy and safety profile of a tailored eradication (TR) strategy based on the presence of a 23S ribosomal RNA point mutation with those of empirical bismuth-based quadruple therapy (EBQT) for first-line eradication of *Helicobacter pylori* (*H. pylori*) in Korean patients.

Cited by: 4 Author: Youn I Choi, Jun Won Chung, Dong Kyun...

Published Year: 2019



Helicobacter pylori

Symptoms Diagnosis

Helicobacter pylori, previously known as *Campylobacter pylori*, is a gram-negative, microaerophilic, spiral bacterium usually

Tailored eradication vs empirical bismuth-containing ...
<https://pubmed.ncbi.nlm.nih.gov/31857776>
Background: Few studies have compared the efficacy and safety profile of a tailored eradication (TR) strategy based on the presence of a 23S ribosomal RNA point mutation with those of empirical bismuth-based quadruple therapy (EBQT) for first-line eradication of *Helicobacter pylori* (H. pylori) in Korean patients. Aim: To compare the efficacy and safety of a TR strategy and those of EBQT ...
Cited by: 7 Author: Youn I Choi, Jun Won Chung, Dong Kyun...
Publish Year: 2019

Randomized Clinical Trial Comparing Concomitant and ...
<https://europepmc.org/article/MED/34207870>
Jun 09, 2021 - Given that the choice of eradication therapy is primarily based on local antibiotic resistance, we consider it is essential to examine the efficacy of tailored and concomitant therapy in H. pylori eradication in the Split-Dalmatia area, knowing that the clarithromycin resistance is above 20% in our region. Therefore, the aim of our study was to compare concomitant nonbismuth quadruple therapy with a tailored therapy ...

- PEOPLE ALSO ASK
- Are there any new treatments for Helicobacter pylori? ▾
 - What is the outcome of H.pylori eradication? ▾
 - Are there any antibiotic resistance for H pylori? ▾

Chat with Bing

You can chat with an alive search engine, excited?

Say something...




Helicobacter pylori

- Symptoms
- Diagnosis
- Causes
- Treatments

Helicobacter pylori, previously known as Campylobacter pylori, is a gram-negative, microaerophilic, spiral bacterium usually found in the stomach. Its helical shape is thought to have evolved in order to penetrate the mucoid lining of the stomach and thereby establish infection. The bacterium was first identified in 1982 by Australian doctors Barry Marshall and Robin Warren. H. pylori has been associated with lymphomas of the mucosa-associated lymphoid tissue in the stomach, esophagus, colon, rectum, or tissues around the eye, and of lymphoid tissue in the stomach.

Wikipedia



1 Name of Journal: *World Journal of Gastroenterology*
Manuscript NO: 67692
Manuscript Type: ORIGINAL ARTICLE

Case Control Study

Tailored eradication strategy vs concomitant therapy for Helicobacter pylori eradication treatment in Korean patients

Tailored eradication therapy vs concomitant regimen for Helicobacter pylori eradication

Youn I Choi, Jun Won Chung, Kyoung Oh Kim, Kwang An Kwon, Yoon Jae Kim, Jung-Ho Kim, Ja Young Seo, Dong Kyun Park

Match Overview

1 Internet 115 words
created on 06-Apr-2021
#publishing bibb core windows.net

国内版

国际版

Tailored eradication strategy vs concomitant therapy for Helicobac



ALL

IMAGES

VIDEOS

12,000 Results

Any time ▾

Tailored eradication vs empirical bismuth-containing ...

<https://pubmed.ncbi.nlm.nih.gov/31857776>

Background: Few studies have compared the efficacy and safety profile of a **tailored eradication (TR) strategy** based on the presence of a 23S ribosomal RNA point mutation with those of empirical bismuth-based quadruple **therapy (EBQT)** for first-line **eradication of Helicobacter pylori (H. pylori) in Korean patients**. Aim: To compare the efficacy and safety of a TR **strategy** and those of EBQT ...

Cited by: 8

Author: Youn I Choi, Jun Won Chung, Dong Kyun...

Publish Year: 2019

Tailored Therapy Versus Empiric Chosen Treatment for ...

<https://europepmc.org/article/MED/26886617> ▾

Feb 01, 2016 · INTRODUCTION. Since the discovery of **Helicobacter pylori** in 1982, research has been conducted over decades to explore the optimal **eradication strategy**. 1–3 According to Kyoto global consensus report, H **pylori**-induced gastritis is classified into the category of infectious disease. 4 However, the **strategy** of H **pylori** **eradication** is difficult to follow the common **treatment** protocols of ...

Cited by: 27

Author: Han Chen, Yini Dang, Xiaoying Zhou, Bin...

Publish Year: 2016

Comparative Study of Helicobacter Pylori Eradication Rates ...

<https://pubmed.ncbi.nlm.nih.gov/29369454>

Background: The standard triple **Helicobacter pylori** regimen now shows unacceptably low **treatment** success in Korea. Administration of the **concomitant therapy** for 10 days, which has a high cure rate, is recommended as an alternative first-line **treatment** in areas of ...

Cited by: 22

Author: Jung Wan Choe, Sung Woo Jung, Seung ...

Publish Year: 2018

Randomized Clinical Trial Comparing Concomitant and ...

<https://europepmc.org/article/MED/34207870> ▾

Jun 09, 2021 · Given that the choice of **eradication therapy** is primarily based on local antibiotic resistance, we consider it is essential to examine the efficacy of **tailored and concomitant therapy** in H. **pylori** **eradication** in the Split-Dalmatia area, knowing that the clarithromycin resistance is above 20% in our region . Therefore, the aim of our study was to compare **concomitant nonbismuth quadruple therapy** with a **tailored therapy** ...